Thus, we suggest that in the heterozygotes both allotypes of ERAP1 could in total utilize a broader spectrum of substrates and the chance of generation of more immunogenic cancer epitope(s) is much greater than in the case of homozygotes. The gene discussed is ERAP1; the disease is cancer.